Table 2.
Baseline characteristics of Type 2 diabetes.
| Total (n = 517) |
≥F3 (n = 155) |
F0~2 (n = 362) |
p | |
|---|---|---|---|---|
| Age (years) † | 53.8 ± 12.9 | 57.5 ± 12.2 | 52.2 ± 12.9 | <0.001 a |
| Male | 46.6% | 41.9% | 48.6% | 0.194 b |
| BMI (kg/m2) † | 29.36 ± 5.16 | 29.41 ± 4.48 | 29.33 ± 5.43 | 0.865 a |
| Waist circumference (cm) † | 96.50 ± 13.54 | 98.28 ± 7.75 | 95.90 ± 14.99 | 0.266 a |
| Hypertension | 58.6% | 65.8% | 55.4% | 0.036 b |
| Triglyceride (mg/dL) † | 164.89 ± 96.71 | 141.09 ± 64.46 | 175.49 ± 106.39 | <0.001 a |
| HDL-CROL (mg/dL) † | 46.27 ± 15.00 | 47.60 ± 17.15 | 45.68 ± 13.92 | 0.226 a |
| Cholesterol (mg/dL) | 188.12 ± 55.16 | 122.30 ± 82.12 | 116.31 ± 38.01 | 0.444 a |
| Albumin (mg/dL) | 4.29 ± 0.46 | 4.20 ± 0.47 | 4.32 ± 0.45 | 0.005 a |
| Glucose (mg/dL) † | 141.41 ± 45.07 | 142.56 ± 46.87 | 140.91 ± 44.34 | 0.711 a |
| AST (IU/L) † | 58.79 ± 37.09 | 65.35 ± 33.84 | 55.99 ± 38.10 | 0.006 a |
| ALT (IU/L) † | 78.29 ± 56.08 | 75.90 ± 47.52 | 79.31 ± 59.39 | 0.490 a |
| AST/ALT † | 0.8786 ± 0.3993 | 0.9893 ± 0.4348 | 0.8312 ± 0.3738 | <0.001 a |
| Platelets (×109/L) † | 217.78 ± 73.41 | 183.91 ± 73.51 | 232.279 ± 68.52 | <0.001 a |
| FIB-4 index † | 2.07 ± 1.73 | 3.02 ± 2.20 | 1.67 ± 1.29 | <0.001 a |
| NAFLD fibrosis score † | −0.58 ± 1.45 | 0.16 ± 1.56 | −0.91 ± 1.27 | <0.001 a |
| Steatosis (mean ± SD) | 1.74 ± 0.86 | 1.77 ± 0.68 | 1.73 ± 0.92 | 0.805 a |
| Inflammation (mean ± SD) | 1.56 ± 0.90 | 1.86 ± 0.80 | 1.44 ± 0.91 | 0.006 a |
| Hepatic fibrosis (%) | 30.0% | 155 | 362 | |
| F0/1 | 228 (63.0%) | |||
| F2 | 134 (37.0%) | |||
| F3 | 112 (72.3%) | |||
| F4 | 43 (27.7%) |
Data are expressed as number (percent). † Data are shown as mean ± standard deviation. Abbreviations: AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index; HDL, high-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; a Student’s t-test; b Chi-square test.